KIDRON NADAV 4
4 · ORAMED PHARMACEUTICALS INC. · Filed Jan 6, 2025
Insider Transaction Report
Form 4
KIDRON NADAV
DirectorPresident and CEO
Transactions
- Award
Common Stock
2025-01-02+433,500→ 2,259,598 total
Holdings
- 126,000(indirect: By wholly-owned corporation)
Common Stock
Footnotes (1)
- [F1]Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 36,125 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.